. 2023 Apr 7;58(2):83–90. doi: 10.5045/br.2023.2023005
© 2023 Korean Society of Hematology
This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Fig. 3.
Daratumumab dose intensity per cycle.